201.90
Overview
News
Price History
Option Chain
Financials
Why WST Down?
Discussions
Forecast
Stock Split
Dividend History
West Pharmaceutical Services Inc stock is traded at $201.90, with a volume of 1.68M.
It is down -3.46% in the last 24 hours and down -12.77% over the past month.
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
See More
Previous Close:
$209.13
Open:
$206.93
24h Volume:
1.68M
Relative Volume:
1.70
Market Cap:
$15.37B
Revenue:
$2.88B
Net Income/Loss:
$499.60M
P/E Ratio:
29.96
EPS:
6.74
Net Cash Flow:
$321.60M
1W Performance:
-0.91%
1M Performance:
-12.77%
6M Performance:
-30.06%
1Y Performance:
-46.50%
West Pharmaceutical Services Inc Stock (WST) Company Profile
Name
West Pharmaceutical Services Inc
Sector
Industry
Phone
(610) 594-2900
Address
530 HERMAN O. WEST DRIVE, EXTON, PA
Compare WST with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
WST
West Pharmaceutical Services Inc
|
201.90 | 15.37B | 2.88B | 499.60M | 321.60M | 6.74 |
![]()
ISRG
Intuitive Surgical Inc
|
482.74 | 175.60B | 8.35B | 2.32B | 1.30B | 6.41 |
![]()
BDX
Becton Dickinson Co
|
198.71 | 59.07B | 20.64B | 1.73B | 2.94B | 6.02 |
![]()
ALC
Alcon Inc
|
92.54 | 44.80B | 9.91B | 1.02B | 665.00M | 2.05 |
![]()
RMD
Resmed Inc
|
212.91 | 31.51B | 4.93B | 1.25B | 1.38B | 8.47 |
![]()
COO
The Cooper Companies, Inc.
|
79.51 | 15.75B | 3.90B | 392.30M | 288.10M | 1.95 |
West Pharmaceutical Services Inc Stock (WST) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-18-25 | Initiated | Evercore ISI | Outperform |
Feb-14-25 | Upgrade | Deutsche Bank | Hold → Buy |
Jan-08-25 | Initiated | Citigroup | Buy |
Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
Dec-12-24 | Upgrade | UBS | Neutral → Buy |
Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
Jun-16-23 | Upgrade | BofA Securities | Neutral → Buy |
Apr-11-23 | Upgrade | Stephens | Equal-Weight → Overweight |
Dec-14-22 | Initiated | Deutsche Bank | Hold |
Nov-30-22 | Initiated | UBS | Neutral |
Oct-28-22 | Downgrade | BofA Securities | Buy → Neutral |
Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
Oct-14-20 | Initiated | Stephens | Equal-Weight |
Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
Apr-24-20 | Upgrade | BofA/Merrill | Underperform → Neutral |
Dec-12-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
Jul-26-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
May-01-19 | Downgrade | Jefferies | Buy → Hold |
Apr-23-19 | Initiated | William Blair | Outperform |
Apr-25-18 | Downgrade | BofA/Merrill | Neutral → Underperform |
Jan-24-18 | Initiated | Goldman | Neutral |
Oct-17-17 | Downgrade | BofA/Merrill | Buy → Neutral |
Oct-03-17 | Initiated | Stephens | Equal-Weight |
Sep-15-17 | Upgrade | Jefferies | Hold → Buy |
Oct-28-16 | Upgrade | Wells Fargo | Market Perform → Outperform |
Sep-21-16 | Downgrade | Wells Fargo | Outperform → Market Perform |
Mar-22-16 | Initiated | Wells Fargo | Outperform |
May-14-10 | Reiterated | UBS | Neutral |
Feb-23-10 | Initiated | Jefferies & Co | Buy |
Dec-19-08 | Initiated | UBS | Neutral |
View All
West Pharmaceutical Services Inc Stock (WST) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
West Pharmaceutical Services, Inc. (WST): One of the Low Profile Dividend Champions to Buy - Yahoo Finance
Earnings Preview: West Pharmaceutical Services (WST) Q1 Earnings Expected to Decline - Yahoo Finance
West Pharmaceutical Services, Inc. (NYSE:WST) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
West Pharmaceutical Services (WST) Expected to Announce Earnings on Thursday - Defense World
West to Host Second-Quarter 2024 Conference Call - Quantisnow
Agree To Purchase West Pharmaceutical Services At $180, Earn 11.2% Annualized Using Options - Nasdaq
Fill Finish Manufacturing Market to Witness Upsurge in Growth - openPR.com
West Pharmaceutical price target lowered to $280 from $285 at BofA - Yahoo Finance
UGI Corporation to Announce Q2 2025 Results with Live Webcast - MyChesCo
West Pharmaceutical Announces Departure of Senior Executive - TipRanks
BofA Securities Cuts West Pharmaceutical Services Price Target to $280 From $285, Maintains Neutral Rating - marketscreener.com
West Pharmaceutical Services to Announce Q1 2025 Results with Live Webcast and Q&A Session - MSN
Zacks Research Issues Positive Outlook for WST Earnings - Defense World
Wellington Management Group LLP Buys 99 Shares of West Pharmaceutical Services, Inc. (NYSE:WST) - Defense World
West Pharmaceutical Services Earnings Preview: What to Expect - MSN
West Pharmaceutical Services, Inc.'s (NYSE:WST) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - Yahoo Finance
Zacks Research Analysts Reduce Earnings Estimates for WST - Defense World
Penn College lab named in honor of West Pharmaceutical Services - Penn State University
College lab named in honor of West Pharmaceutical Services - Pennsylvania College of Technology
WST ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of West Pharmaceutical Services, Inc. Shareholders Who Lost Money - ACCESS Newswire
The Latest Breaking News on West Pharmaceutical Services Earnings Preview: What to Expect - Inkl
West Pharmaceutical Services Earnings Preview: What To Expect - Barchart.com
West to Host First-Quarter 2025 Conference Call - The Malaysian Reserve
Mark Your Calendar: West Pharmaceutical Announces Critical Q1 2025 Earnings Date - Stock Titan
Will Weakness in West Pharmaceutical Services, Inc.'s (NYSE:WST) Stock Prove Temporary Given Strong Fundamentals? - simplywall.st
West Pharmaceutical Services Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
West Pharmaceutical Services, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsWST - ACCESS Newswire
West Pharmaceutical stock hits 52-week low at $196.78 - Investing.com Australia
West Pharmaceutical stock hits 52-week low at $196.78 By Investing.com - Investing.com India
Analysis of China-to-West pharmaceutical licensing deals in 2024 - Nature
ATTENTION WST SHAREHOLDERS: Investors who Lost Money on West Pharmaceutical Services, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation - ACCESS Newswire
Trump administration shutters DC foreign policy think tank Wilson Center - MarketScreener
Teacher Retirement System of Texas Takes Position in West Pharmaceutical Services, Inc. (NYSE:WST) - Defense World
West Pharmaceutical Services, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsWST - ACCESS Newswire
National Wealth Management Group LLC Makes New $706,000 Investment in West Pharmaceutical Services, Inc. (NYSE:WST) - MarketBeat
Pharmaceutical Testing Services Market Set to Witness - openPR.com
Delcath Systems (NASDAQ:DCTH) and West Pharmaceutical Services (NYSE:WST) Critical Survey - Defense World
WST ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your West Pharmaceutical Services, Inc. investment - ACCESS Newswire
Commonwealth Equity Services LLC Trims Stake in West Pharmaceutical Services, Inc. (NYSE:WST) - Defense World
How Is The Market Feeling About West Pharmaceutical Servs? - Benzinga
West Pharmaceutical Services, Inc. (WST) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services Stocks - Yahoo Finance
West Pharmaceutical Services, Inc. (NYSE:WST) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
West Pharmaceutical Services: Bylaw Changes and Share Price Dynamics - AInvest
West Pharmaceutical Services (NYSE:WST) Proposes Bylaw Changes; Share Price Remains Flat - Yahoo Finance
Is West Pharmaceutical Services Stock Underperforming the S&P 500? - Nasdaq
Is West Pharmaceutical Services Stock Underperforming The S&P 500? - Barchart.com
West Pharmaceutical at KeyBanc Forum: Strategic Growth Amid Challenges - Investing.com
West Pharmaceutical Services Inc Stock (WST) Financials Data
Revenue
Net Income
Cash Flow
EPS
West Pharmaceutical Services Inc Stock (WST) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Reiss-Clark Cindy | Chief Commercial Officer |
Feb 18 '25 |
Option Exercise |
211.00 |
246 |
51,940 |
5,131 |
MacKay Kimberly Banks | SVP, GC & Corporate Secretary |
Feb 18 '25 |
Option Exercise |
211.00 |
246 |
51,940 |
1,605 |
Favorite Annette F | Sr. VP & Chief HR Officer |
Feb 18 '25 |
Option Exercise |
211.00 |
246 |
51,940 |
6,823 |
Winters Chad | VP, Chief Accounting Officer |
Feb 18 '25 |
Option Exercise |
211.00 |
82 |
17,313 |
1,391 |
Witherspoon Charles | VP & Treasurer |
Feb 18 '25 |
Option Exercise |
211.00 |
66 |
13,864 |
1,319 |
Green Eric Mark | President, CEO and Board Chair |
Feb 18 '25 |
Option Exercise |
211.00 |
2,461 |
519,269 |
170,369 |
Witherspoon Charles | VP & Treasurer |
Oct 29 '24 |
Option Exercise |
173.22 |
478 |
82,799 |
1,956 |
Witherspoon Charles | VP & Treasurer |
Oct 29 '24 |
Sale |
310.40 |
703 |
218,211 |
1,253 |
Abraham Silji | SVP, Chief Technology Officer |
Oct 29 '24 |
Option Exercise |
0.00 |
458 |
0 |
3,318 |
Witherspoon Charles | VP & Treasurer |
Aug 19 '24 |
Option Exercise |
102.51 |
529 |
54,228 |
2,507 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):